Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xizang Weixinkang Pharmaceutical Co Buyback Yield % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Xizang Weixinkang Pharmaceutical Co's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xizang Weixinkang Pharmaceutical Co Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Xizang Weixinkang Pharmaceutical Co's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Xizang Weixinkang Pharmaceutical Co's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xizang Weixinkang Pharmaceutical Co (SHSE:603676) has a Buyback Yield % of 0.00 as of Aug. 14, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Xizang Weixinkang Pharmaceutical Co and its competitors. According to the industry distribution chart, Xizang Weixinkang Pharmaceutical Co ranks #999999 out of 271 companies in the Drug Manufacturers industry.
Is Xizang Weixinkang Pharmaceutical Co's Buyback Yield % too high?
Xizang Weixinkang Pharmaceutical Co's current Buyback Yield % is 0.00. Based on the distribution chart, Xizang Weixinkang Pharmaceutical Co ranks #999999 out of 271 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Xizang Weixinkang Pharmaceutical Co has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Xizang Weixinkang Pharmaceutical Co's Buyback Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Xizang Weixinkang Pharmaceutical Co ranks #999999 out of 271 companies for Buyback Yield %. This places Xizang Weixinkang Pharmaceutical Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Xizang Weixinkang Pharmaceutical Co and its competitors. Xizang Weixinkang Pharmaceutical Co's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xizang Weixinkang Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Xizang Weixinkang Pharmaceutical Co (SHSE:603676) is currently considered Fairly Valued. The stock's GF Value™ is ¥8.91, compared to a current price of ¥9.35 — trading 4.9% above its estimated fair value. The current Buyback Yield % is 0.00. Xizang Weixinkang Pharmaceutical Co's overall GF Score™ is 78/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Xizang Weixinkang Pharmaceutical Co (SHSE:603676), the current Buyback Yield % is 0.00 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xizang Weixinkang Pharmaceutical Co (SHSE:603676) Overvalued in 2026?
Based on GuruFocus' analysis, Xizang Weixinkang Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥9.35 is trading 4.9% above its estimated GF Value™ of ¥8.91.
GuruFocus considers Xizang Weixinkang Pharmaceutical Co to be Fairly Valued.
Key valuation signals for SHSE:603676:
Buyback Yield %: 0.00
GF Value™: ¥8.91 vs. price of ¥9.35 (4.9% above fair value)
No single metric tells the full story. See the SHSE:603676 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AddressYuanqu South Road, 3rd Floor, Building 4, Industrial Center, No. 5, Zone B, Lhasa Economic and Technological, Development Zone, Tibet Autonomous Region, Lhasa, CHN, 850000
Xizang Weixinkang Pharmaceutical Co Ltd is engaged in research & development, production and sales of chemical pharmaceutical preparations and their raw materials. It also produces and sells liver protection drugs and antibiotic products.
78GF Score
Get the complete analysis for SHSE:603676
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603676 has been successfully added to your 
